100results about How to "Improve sensitivity and specificity" patented technology

An implantable medical device and method are provided for assessing autonomic tone and risk factors associated with arrhythmias and, based on this assessment, an early recurrence of ventricular tachycardia or ventricular fibrillation is predicted. Specifically, changes in R—R interval, heart rate variability, patient activity, and myocardial ischemia are measured prior to and after a detected an arrhythmia episode. A recurrence score is calculated as a weighted sum of measured parameters and compared to a prediction criterion. The prediction criterion may be a preset threshold score or an individualized episode template based on previously calculated recurrence scores associated with recurring episodes. Stored parameters and episode-related data may be downloaded for offline analyses for optimizing prediction criteria and monitoring patient status.

The invention discloses a CRISPR-based Escherichia coli O157:H7 strain detection reagent box and a detection method and belongs to the technical field of molecular biology. The detection reagent box comprises primers designed for a CRISPR1 locus gene sequence or a homologous sequence with homology reaching higher than 95% of an Escherichia coli O157:H7 strain and shown as SEQ ID NO.1 and SEQ ID NO.2 in a sequence table. The primers are utilized for PCR amplification, and three unique spacer sequences (shown as SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7) of CRISPR1 are detected to be bacterially positive in an amplification product. The detection method is simple to operate, high in sensitivity and specificity, uniform with serotyping result of Escherichia coli O157:H7 and low in detection expense and has good popularization and application value.

The invention discloses a method and device for detecting gene fusion of target areas and a storage medium. The method comprises a comparison result obtaining step, a target area information extraction step, a paired extension area information extraction step, an information annotation step, a breakpoint statistic scoring step, a local clustering step and a local splicing step. According to the method, advantages of double-tail end sequencing reads and comparison information are sufficiently utilized, the detection process does not re-comparison and a complicated assembling process, and the target area can detect gene fusion events through covering one fusion area, so that the sensitivity and specificity of detecting the gene fusion of target areas are greatly enhanced while the resource demand and detection speed are optimized.

In a method, a computer and a medical computer for automatic failure analysis in order to provide a cause of failure of the medical imaging apparatus during operation, input data are read into the computer that include raw data or image data, acquired by the imaging apparatus. A set of performance indicators in the input data is calculated by the computer. A trained neural network system is accessed with the calculated performance indicators, in order to provide result data that, in the case of a failure, identify a failure source.

A optical Biopsy method and an apparatus are used in the diagnosis of precancerous lesion for locating the place and determining the level of malignant tumor. The apparatus comprises light source (1, 10) a light channel system, an endoscope (21) and a circuit system. The light sources include an excited light (1) and a cold light source (10). The cold light source and the excited light in the light channel system go through the end of the light guide of the endoscope via optical fiber bundle and irradiate the tested living tissue (22). The white light image signal and the intrinsic fluorescence image signal reflected from the tested living tissue (22) are received by a weak fluorescence CCD (6) that tightly connects to the end of the endoscope (21) and then transmit to the circuit system via a signal wire (9) to produce the image in the display (17). The weak fluorescence signal reflected from the tested living tissue (22) is transmitted to the circuit system via the weak fluorescence fiber bundle (4) protruding from the forceps hole of the endoscope to produce the spectrum image (16).

A pattern VEP system for screening for glaucoma and other optic nerve related diseases/deficiencies. The system combines high contrast and low contrast testing. The low contrast testing allows for highly sensitive glaucoma testing and the high contrast allows for a sensitive test of the central vision. The system also includes a narrowly tailored method of rejecting corrupted data allowing the system to selectively salvage useful portions of a signal. The system also provides a method of data modeling to locate the N75-P100-N135 complex in a waveform and determine if it falls within the normal range

The invention discloses a detection kit for identifying and diagnosing whether an equine animal is infected with piroplasmosis or not, and a preparation method and a using method thereof. A detection film for detecting equine piroplasmosis and a piroplasmosis universal primer are arranged in the kit for detecting the equine piroplasmosis. The using method of the kit comprises the following steps:extracting DNA (deoxyribonucleic acid) from blood of a horse to be detected, further using the piroplasmosis universal primer to perform amplification, combining an amplification product with the detection film, enabling biotin at the terminal of a PCR (polymerase chain reaction) product to be in action with streptavidin-peroxidase, and then playing a catalysis role in enabling a substrate of peroxidase, namely an enhanced chemiluminescence reagent (ECL-detection) to emit fluorescence, thereby exposing an X-photosensitive film; and performing development and fixing treatment on the film so asto emerge a shadow in a region corresponding to specificity hybridization of a probe on the detection film and the PCR product, and further judging whether the detected animal is infected with the piroplasmosis or not according to whether the shade is left on the film or not.

The present invention relates to diagnostic methods that are relevant to various solid tumor cancers that are not amenable to traditional BIH3 profiling diagnostic methods. In some embodiments, the methods described herein are useful in the evaluation of a patient, for example, for evaluating diagnosis, prognosis, and response to treatment. In various aspects, the present disclosure includes evaluating a solid tumor or cancer. In various embodiments, the evaluation may be selected from diagnosis, prognosis, and response to treatment. In various embodiments, the present disclosure directs the treatment of a cancer patient, including, for example, what type of treatment should be administered or withheld. In some embodiments, the present disclosure includes the measurement of a tumor cell, sample, and/or specimen, including biopsy or surgical specimen samples.

A reaction mixture for a polymerase chain reaction (PCR) includes water, DNA polymerase, deoxyribonucleoside triphosphates (dNTPs), tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), potassium chloride, magnesium chloride, dithiothreitol (DDT), and an additive agent. The reaction mixture is capable of enhancing the sensitivity and specificity of PCR and increasing the yield of correct nucleic acid sequence copies when being used in PCR.

The invention discloses a real-time fluorescent RT-PCR method for detecting whether arabis mosaic virus, bean yellow mosaic virus and lily symptomless virus infect a host. In the invention, according to the RNAs of the arabis mosaic virus, the bean yellow mosaic virus and the lily symptomless virus, a specific amplimer and a fluorescent probe are designed, RT-Realt time PCR reaction is carried out the RNA template of virus to be identified by means of the specific amplimer and the fluorescent probe, and whether the arabis mosaic virus, the bean yellow the mosaic virus and the lily symptomless virus infect the host is rapidly detected by carrying out real-time fluorescent detection on RT-Real time PCR products.

The present invention belongs to the field of bio-medicine, relates to a liver fibrosis serum N-glycome peak mark, and specifically relates to a method for detecting the chronic hepatitis B liver fibrosis serum N-glycome peak mark and the application thereof. The method detects a serum sample of a chronic HBV infected patient by using DSA-FACE technology to obtain a glycome map with peak values. After the peak values are quantified, the non-traumatic chronic hepatitis B liver fibrosis serum N-glycome peak mark is obtained by using the internal reference corrected data. The method of the invention can help to significantly improve the specificity and the sensitivity of non-traumatic diagnosis for chronic hepatitis B liver fibrosis, can help to efficiently predict the degree of liver fibrosis in chronic hepatitis B with the N-glycome peak mark as a non-traumatic alternative indicator, and has clinical significance in reality for prognosis estimation, treatment option and treatment evaluation.

The invention discloses a plasma exosome tRFs marker and an application thereof to breast cancer diagnosis. The marker is an exosome-derived tRF-Ser-AGA-018. The application of the marker includes theoperating steps: A building a unified specimen bank and a database, acquiring blood samples and tissue samples conforming to standards by standard operating procedures, and systematically collectingcomplete clinical data of included crowds; B analyzing tumor-induced exosome-derived tRFs disparity expression spectra in blood, selecting plasma samples of breast cancer cases and healthy persons, breast cancer tissues and para-carcinoma tissues, extracting exosomes, sequencing tRFs and tiRNA and screening out differentially expressed tRFs; C performing QRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) analysis on the screened differentially expressed tRFs in large sample crowds. The tumor-induced exosome tRFs in the blood is a novel biomarker which realizes stability, minimal invasiveness and real-time monitoring, the sensitivity and the specificity of disease diagnosis are greatly improved, and successful development of the non-coding RNA (ribonucleic acid) biomarker is beneficial to breast cancer diagnosis.

The invention belongs to the technical field of biology and particularly relates to a molecular marker for diagnosis of breast cancer and an application of the molecular marker. The molecular marker is FMOD (fibromodulin), a breast cancer diagnosis product based on the molecular marker is further provided, the fact that the FMOD promotes the metastasis of breast cancer by activating the activity of Wnt/beta-catenin signaling pathway is illuminated, a theoretical basis is provided for clinical application of the FMOD as a novel target in tumor, a novel treatment is provided for breast cancer, and a reliable biological diagnosis target is provided for prognosis of the tumor treatment and early metastasis diagnosis.

The invention belongs to the technical field of bio-detection and particularly discloses a kit of high-effectively and quantitatively detecting Golgi apparatus 73 (GP73). In the invention, for the first time, an anti-GP73 polyclonal antibody and an anti-GP73 monoclonal antibody are mixed to obtain a combined capture antibody. The technology, instead of a conventional method in which only is one of the anti-GP73 polyclonal antibody or the anti-GP73 monoclonal antibody employed as a capture antibody, can significantly improve specificity and sensitivity of immune-detection and achieve a lower detection limit since the two antibodies hereinabove are mixed. The kits in the invention have strong specificity and sensitivity, lower detection limit and good linearity conditions.

Novel synthetic enzyme substrates with improved enzymatic specificity are disclosed. These synthetic enzyme substrates consist of a substrate peptide that has had its specificity further improved by additional synthetic moieties, selected by combinatorial chemistry techniques, that act to sterically block non-target enzymes. These “steric restrictor” moieties may be labeled to produce a detectable signal upon enzymatic reaction. These novel substrates are particularly useful for improved enzyme substrate microarrays. Specific applications for improved protease substrate microarrays are discussed. A variety of applications for these improved protease substrate microarrays are also disclosed, including proteomics research, protease discovery, protease binding site characterization, diagnosis of the protease composition of biological samples, monitoring the angiogenic status of a tumor, monitoring the status of arthritis and other inflammatory diseases, and the discovery and optimization of novel drugs that modify or inhibit protease activity. The same techniques may also be used to design improved enzyme inhibitors.

The invention discloses one group of methylated genes and a detection method thereof. The group of methylated genes comprises genes p16, DLEC1, CDH1, DAPK and RUNX3; DNA (Deoxyribonucleic Acid) gene sequences are SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 respectively. In a free DNA sample of plasma of a patient suffering from a lung cancer, specific CpG (Cytosine-Phosphate-Guanine) loci of the genes generate hypermethylation. Those genes provided by the invention are biomarkers for the lung cancer, can be used as a foundation for designing a diagnostic reagent for the lung caner, are applicable to the early auxiliary detection of the lung cancer in a hospital, and can be used for carrying out early risk evaluation on a lung-cancer high risk group.

The invention relates to a rapid detecting mycoplasma ovipneumoniae method, according to the gene sequence of the detected mycoplasma ovipneumoniae designing a LAMP primer; establishing a reaction system for LAMP visualization method, and conducting optimizations for LAMP reaction conditions; gathering and embrocating the sheep nasal secretions, preparing DNA template solution, conducting detections using the optimized reaction system and reaction condition. The method targets the shortcomings of requiring professional instruments and labs and the like in detecting mycoplasma ovipneumoniae in the existing methods, which limits the promotion and application of these diagnosis methods in clinics, and establishes a rapid detecting LAMP visualization method to detect MO, the method has very high specificity and sensitivity, and provides a rapid, simple, and accurate detection method for clinical diagnoses of sheep MO infection.

The invention belongs to the fields of analytical chemistry and clinical medicine and discloses a plasma metabolism micromolecular marker related to human intestinal canal aganglionosis and an application of the plasma metabolism micromolecular marker. The plasma metabolism micromolecular marker is one or more than one of phenylpropyl tryptophan, succinyl carnitine and gamma-glutamoyl glutamic acid. The plasma metabolism micromolecular marker has specificity and sensibility on intestinal canal aganglionosis. A kit provided by the invention adopts UPLC-MS (ultra performance liquid chromatography-mass spectrometry) and can accurately detect phenylpropyl tryptophan, succinyl carnitine and gamma-glutamoyl glutamic acid in plasma, better auxiliary information can be provided for diagnosing intestinal canal aganglionosis, invasive diagnosis can be avoided, screening and diagnosis can be carried out in early stage, repeated detection can be realized, and dynamic monitoring is easy to realize.

The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery.

Provided herein are in situ generated conformationally constrained peptide arrays, methods for synthesizing such arrays, and methods, systems and assays comprising the use of the synthesized constrained peptide arrays for characterizing protein-target Interactions including: antibody-target interactions, receptor agonist interactions, receptor antagonist interactions, enzyme substrate interactions, enzyme inhibitor interactions, and other protein-protein interactions.

The invention discloses a gene mutation for diagnosing Marfan syndrome. The mutation is c.5651_5664del:p.D1884fs. Through second-generation sequencing, it is founded that c.5651_5664del on a FBN1 geneexists in a genome of a patient who is diagnosed with Marfan syndrome, but the mutation is not found in control population, so the gene mutation can be used as biomarkers for the diagnosis of Marfansyndrome.

Provided herein are media, methods, kits, primers and oligonucleotide probes for use in the molecular detection of pathogens. These may be used in combination for the rapid, high-throughput screening PCR-based techniques to simultaneously detect multiple pathogens. The multiplex-detection methods have improved sensitivity and specificity for the detection of multiple pathogens simultaneously. Real-time PCR assaying techniques using such primers include microarrays and multiplex arrays, the latter optionally simultaneously with oligonucleotide TaqMan probes.

The invention relates to a dairy cow ketosis diagnostic kit and a detecting method of the dairy cow ketosis diagnostic kit. The dairy cow ketosis diagnostic kit comprises a reagent 1, a reagent 2, a reagent 3, a detector and a standard colorimetric board, wherein the reagent 1 is a mixture of diaphorase, nicotinamide adenine dinucleotide and beta-hydroxybutyrate dehydrogenase, the reagent 2 is a mixed salutation of dimethyl sulfoxide, disodium hydrogen phosphate, magnesium chloride, sodium azide and sodium nitrite, and the reagent 3 is a thiazolyl blue solution. The detection method of the dairy cow ketosis diagnostic kit comprises the following steps: firstly separating a ketone body from milk, then adding a prepared mixed solution of the reagent 1, the reagent 2 and the reagent 3, and a to-be-detected sample into a feeding hole of the detector, after reacting for 3 minutes, comparing the result with the standard colorimetric board so as to determine a detecting result. The dairy cow ketosis diagnostic kit is convenient to operate, high in specificity and sensitivity, and good in repeatability, thus having a wide market application prospect.

The invention discloses a preparation method of a protein chip used for screening lung cancer. The preparation method is characterized in that smoker lung cancer tissue T7 bacteriophage is constructedto display a cDNA library, a cDNA fragment in the library is inserted into a T7 bacteriophage carrier, the inserted fragment is displayed on the bacteriophage coat protein with a fusion protein form,an exogenous protein or a polypeptide gene and a bacteriophage specific protein gene are subjected to fusion expression on the surface, through biopanning and phage display technologies, the proteinchip is prepared, the abnormal gene of the patient is subjected to fusion expression to the abnormal protein, and high flux screening of the protein chip and an antigen-antibody specifically binding principle are used for determining a tumor marker. The method can be used for screening primary tumor at an early stage, is capable of screening tumour high-risk population, discriminating benign and malignant tumour, determining a tumour development process, and observing the tumour treatment effect, and performs important effect for tumour recurrence prediction and prognosis.

The present invention provides a composition, a kit and the use thereof, as well as the method for detecting the cell proliferative abnormality in individuals or grading the disease degree in the individuals. The composition comprises nucleic acids for detecting the methylation level within at least one target region of a gene and the fragment thereof.